An epidemiological study of neovascular age-related macular degeneration in Germany

Current Medical Research and Opinion

Volumn 29, Issue 10, 2013, Pages 1391-1397

  Krause, Lothar ^a   Yousif, Tarik ^b   Pohl, Karin ^c  

^a DESSAU MEDICAL CENTER   (Germany)

^b Practice ^*  (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

AMD diagnosis; AMD epidemiology; AMD treatment; Neovascular age related macular degeneration; Optical coherence tomography

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; BIOMICROSCOPY; CARDIOVASCULAR DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC PROCEDURE; EPIDEMIOLOGICAL DATA; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; GERMANY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPHTHALMOLOGIST; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; QUESTIONNAIRE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; FEMALE; GERMANY; HUMANS; HYPERTENSION; MACULAR DEGENERATION; MALE; MIDDLE AGED; QUESTIONNAIRES; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES;

EID: 84884483597     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.832184     Document Type: Article

References (26)

1. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653-8 (Pubitemid 28414581)
2. Evans JR, Fletcher AE, Wormald RP. Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the Community. Br J Ophthalmol 2004;88:365-70 (Pubitemid 38333716)
3. Rahmani B, Tielsch JM, Katz J, et al. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology 1996;103:1721-6 (Pubitemid 26403720)
4. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43
5. Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-60
6. Vingerling JR, Dielemans I, Hofman A. The prevalence of age-related maculo-pathy in the Rotterdam Study. Ophthalmology 1995;102:205-10
7. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108: 697-704 (Pubitemid 32238465)
8. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2007;114:92-8 (Pubitemid 46014292)
9. Hawkins BS, Bird A, Klein R, et al. Epidemiology of age-related macular degeneration. Mol Vis 1999;5:26. http://www.ncbi.nlm.nih.gov/pubmed/10562650
10. Justiz Bd. Act on the Marketing of Drugs. Available at: http://www.gesetze-im-internet.de/amg-1976/-4.html. Section 1:4;23, 3 [Last accessed 3 May 2012]
11. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-44 (Pubitemid 44511558)
12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31 (Pubitemid 44511557)
13. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000; 107: 2224-32
14. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibi-zumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56 e744
15. Ivers RQ, Cumming RG, Mitchell P, et al. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58-64 (Pubitemid 28037674)
16. Current opinion of the German Ophthalmological Society, and the Retina Society the Professional Association of German Ophthalmologists. The anti-VEGF therapy for neovascular age-related macular degeneration: Therapeutic Strategies, 2012. Available at: http://www.dog.org/wp-content/uploads/2009/08/ Stellungnahme-Anti-VEGF-Therapie-bei-der-neovaskul%C3%A4ren-Therapeutische- Strategie-Febr-2012-final1.pdf [Last accessed 25 June 2012]
17. Cho M, Athanikar A, Paccione J, et al. Optical coherence tomography features of acute central serous chorioretinopathy versus neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:597-9
18. Ernst BJ, Barkmeier AJ, Akduman L. Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Int Ophthalmol 2010;30:267-70
19. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-908
20. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
21. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48
22. Kaiser PK, Blodi BA, Shapiro H. Angiographic and optical coherence tomo-graphic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75
23. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-7
24. Matsumiya W, Honda S, Bessho H, et al. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol 2011;2011. Article ID: 742020. http://www.ncbi.nlm.nih.gov/pubmed/21772985
25. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
26. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001;20:227-53 (Pubitemid 32149928)